Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Operations (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Cash from Operations for 11 consecutive years, with 17712000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 152.96% to 17712000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 73941000.0, a 212.33% decrease, with the full-year FY2025 number at 73941000.0, down 212.33% from a year prior.
  • Cash from Operations was 17712000.0 for Q4 2025 at Cartesian Therapeutics, down from 15600000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13691000.0 in Q3 2024 to a low of 31460000.0 in Q4 2021.
  • A 5-year average of 12039450.0 and a median of 11998500.0 in 2021 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: tumbled 333.93% in 2021, then skyrocketed 248.57% in 2024.
  • Cartesian Therapeutics' Cash from Operations stood at 31460000.0 in 2021, then soared by 62.34% to 11849000.0 in 2022, then tumbled by 96.52% to 23286000.0 in 2023, then soared by 69.93% to 7002000.0 in 2024, then crashed by 152.96% to 17712000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Cash from Operations are 17712000.0 (Q4 2025), 15600000.0 (Q3 2025), and 17521000.0 (Q2 2025).